Core Viewpoint - The company announced the presentation of clinical data for its core product, Tengogatinib, at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, highlighting its potential in treating advanced cholangiocarcinoma (CCA) patients [1] Group 1: Clinical Data Presentation - Tengogatinib, a novel FGFR inhibitor, shows promising activity in overcoming acquired resistance to previous FGFR inhibitors in CCA patients with FGFR2 alterations [1] - The report includes an analysis of circulating tumor DNA (ctDNA) biomarkers to evaluate the efficacy of Tengogatinib in patients with primary and acquired resistance to FGFR inhibitors, as well as other FGFR mutations or wild-type FGFR [1] - The assessment of genomic alterations in patient ctDNA and the correlation of efficacy based on ctDNA mutation status and patient subgroups were discussed, supporting further research in ongoing Phase III clinical trials [1]
药捷安康-B(02617)于2026年美国临床肿瘤学会胃肠道肿瘤研讨会公布替恩戈替尼单药治疗晚期胆管癌患者的临床数据